What Is Progressive Retinal Atrophy in Dogs and Cats?

Progressive retinal atrophy (PRA) is a group of inherited eye diseases in dogs and cats that causes the light-sensing cells in the retina to slowly deteriorate, eventually leading to blindness. Close to 100 dog breeds carry at least one form of PRA, and the condition has no cure once it begins. What makes PRA especially tricky for owners is that it often starts with subtle night-vision problems that can go unnoticed for months or even years before the dog is clearly struggling in daylight. The genetics behind it are surprisingly varied, the diagnostic tools are more sophisticated than many pet owners realize, and research into gene therapy has produced some genuinely promising results.

What Actually Happens Inside the Eye

The retina lines the back of the eye and contains two main types of photoreceptor cells: rods, which handle low-light and peripheral vision, and cones, which manage color and detail in bright light. In PRA, these photoreceptors degrade and die through a process called apoptosis, a kind of programmed cell death. The specific photoreceptors affected first, and the speed at which they fail, depend on which genetic mutation a dog carries. In some forms, the rods and cones never develop properly from birth. In others, they form normally but begin to break down during the first year or two of life, or sometimes not until middle age.

Research into the cellular mechanisms has shown that mitochondrial oxidative stress plays a role in at least some forms of photoreceptor death. In one mouse model of retinal degeneration, markers of mitochondrial stress were elevated in the photoreceptor layer, and the cells died through a pathway that did not involve the usual caspase enzymes most associated with programmed cell death.¹ This suggests the degeneration in PRA is not a single uniform process but involves different molecular triggers depending on the underlying mutation.

Early Signs and How the Disease Progresses

The first thing most owners notice is that their dog becomes hesitant or clumsy in dim lighting. A dog that used to trot confidently through the house at night starts bumping into furniture or refusing to go down stairs in low light. This happens because the rod photoreceptors, which are responsible for night vision, typically degenerate first. In early-onset forms of PRA, this can become apparent as early as a few months of age. In late-onset forms, the dog might seem perfectly normal until age three, five, or even later.

As the rods continue to die off, the cone photoreceptors follow. Daytime vision narrows and dims. Owners often describe their dog developing a wider, more cautious gait and becoming reluctant to enter unfamiliar spaces. The pupils may appear permanently dilated because the retina is no longer responding normally to light. Many dogs compensate remarkably well using their other senses, especially in familiar environments, so owners sometimes do not realize how much vision has been lost until the dog is placed in a new setting.

On examination, a veterinarian looking at the back of the eye with an ophthalmoscope sees characteristic changes: the reflective layer behind the retina (the tapetum) becomes abnormally bright and changes color because the overlying retinal tissue is thinning. The blood vessels that supply the retina shrink noticeably, and the optic disc at the back of the eye can develop irregular, scalloped borders.² By the time these changes are fully developed, significant vision loss has already occurred.

How PRA Is Diagnosed

A standard eye exam by a veterinary ophthalmologist can often identify PRA once the retinal changes are visible, but the disease frequently begins doing damage well before the back of the eye looks abnormal. This is where electroretinography (ERG) becomes valuable. An ERG measures the electrical response of the retina to flashes of light, essentially testing whether the photoreceptors are firing correctly. In most of the breeds where PRA has been studied using ERG, the electrical responses begin dropping long before the dog shows any behavioral signs of vision loss or any visible changes on ophthalmoscopy.³ This early detection is not just academically interesting; it is the foundation for breeding decisions aimed at removing the disease from affected lines.

ERG is performed under general anesthesia or heavy sedation, with electrodes placed on the cornea. The test can distinguish between rod and cone function by using different light intensities and wavelengths. A dog in the early stages of PRA will show diminished rod responses first, with cone responses declining later. In some early-onset forms, ERG abnormalities are detectable as young as six to eight weeks of age, even though the puppy’s behavior seems completely normal.⁴

DNA testing has become the most practical screening tool for many breeds. Once a specific mutation has been identified for a breed’s form of PRA, a simple cheek swab or blood sample can determine whether a dog is clear, a carrier, or affected. DNA testing does not require anesthesia, can be done at any age, and gives a definitive genetic answer rather than a snapshot of current retinal function. However, DNA tests only work for known mutations in known breeds; a clear result on a specific test does not rule out a different, as-yet-unidentified form of PRA.

The Genetics Behind PRA

PRA is not one disease caused by one gene. It is a collection of diseases with similar clinical outcomes but different genetic roots. This genetic diversity, called heterogeneity, mirrors what is seen in retinitis pigmentosa (RP) in humans, the closest human equivalent of PRA.⁵ The genes involved, the inheritance patterns, and the age of onset all vary depending on the breed and the specific mutation.

Most forms of PRA follow autosomal recessive inheritance, meaning a dog must inherit two copies of the faulty gene (one from each parent) to develop the disease. Dogs with only one copy are carriers: they will never go blind themselves, but they can pass the mutation to their offspring. This is why PRA can seem to appear out of nowhere in a litter from two apparently healthy parents who both happen to carry the same recessive mutation.

One of the most widely distributed mutations causes a form called progressive rod-cone degeneration (prcd). A single point mutation has been found in the same gene across at least 18 different breeds and breed varieties, and dogs that are homozygous for the mutation (carrying two copies) consistently develop the disease.⁶ The prcd mutation is one of the most commonly tested for because it cuts across so many breeds, from Labrador Retrievers to Cocker Spaniels to Miniature Poodles.

Not all PRA follows the recessive pattern, though. In English Mastiffs, researchers identified a naturally occurring dominant mutation in the rhodopsin gene (RHO), the same gene responsible for some forms of dominant retinitis pigmentosa in people. A dog with just one copy of this mutation develops retinal degeneration.⁷ And in Weimaraners, a large deletion in the RPGR gene on the X chromosome causes an X-linked form of PRA, where males are predominantly affected because they have only one X chromosome and therefore no backup copy of the gene.⁸

Even within a single mutation, dogs do not all go blind at the same rate. Research on X-linked PRA in a colony of dogs that all inherited the identical mutant X chromosome found extensive variation in how severely and how quickly the disease progressed.⁹ This means other genes and possibly environmental factors are modifying the disease’s timeline, making it harder to predict exactly when a genetically affected dog will lose useful vision.

Breed-Specific Mutations and Why Testing Matters

Because PRA’s genetic roots differ across breeds, research often proceeds breed by breed. In Irish Setters, one of the earliest forms identified involved a mutation in the gene encoding the beta-subunit of a key enzyme in the visual signaling pathway, causing a severe early-onset rod-cone dysplasia.¹⁰ In Golden Retrievers, a different frameshift mutation in the SLC4A3 gene has been linked to PRA.¹¹ Each new gene discovery adds another test to the toolkit, but it also underscores how many mutations remain undiscovered in breeds where PRA exists but the specific cause has not yet been pinpointed.

Large-scale analysis of commercial genetic testing data has shown that breeding decisions informed by DNA results do reduce the number of affected puppies being born. However, dogs homozygous for the prcd mutation were still appearing more than fourteen years after the test became available, likely because some breeders unknowingly paired two carriers that had never been tested.¹² The takeaway for breeders and puppy buyers is clear: a genetic test only helps if it is actually used, and “my dog’s parents had good eyes” is not the same as “my dog’s parents were genetically cleared.”

Formal eye-examination schemes run by breed clubs and kennel clubs have also contributed to reducing PRA incidence. A 13-year study in German Dachshunds found that the combination of repeated ophthalmologic exams and breeding advice based on those results led to a declining incidence of PRA within the breed.¹³ These programs work best when paired with genetic testing, since eye exams alone cannot identify young carriers whose retinas still look normal.

PRA Versus Sudden Acquired Retinal Degeneration Syndrome

One condition that can look superficially similar to PRA is sudden acquired retinal degeneration syndrome (SARDS). Both diseases end in blindness, and both involve photoreceptor loss, but they are fundamentally different. PRA is inherited, slow, and progressive over months to years. SARDS strikes suddenly, often over days to weeks, in middle-aged dogs with no prior vision problems. Many SARDS dogs are also systemically unwell, showing increased thirst, appetite, and weight gain that suggest broader metabolic disruption.

At the tissue level, the two conditions look different as well. A recent histopathologic study comparing eyes from dogs with SARDS and PRA found that while both had reduced blood vessel density in the choroid layer behind the retina compared to healthy eyes, the relationship between vessel loss and photoreceptor death was tight in PRA but essentially absent in SARDS. Dogs with SARDS also had a significantly thicker Bruch’s membrane, the thin barrier between the retina and its blood supply, than either PRA dogs or healthy controls.¹⁴ The distinction matters because it suggests different underlying disease processes and has implications for any future treatments.

Cats Get It Too

PRA is not exclusively a dog problem. The best-known feline form is rdAc, caused by a mutation in the CEP290 gene. It was originally identified in Abyssinian and Somali cats, but a survey across 41 cat breeds found the mutation in a much wider range of breeds, with affected cats showing retinal degeneration that closely matched the disease seen in Abyssinians.¹⁵ The rdAc mutation is recessive, so carriers show no symptoms, and a DNA test is available.

Interestingly, mutations in the same CEP290 gene cause Leber congenital amaurosis (LCA) in humans, a severe form of childhood blindness. But cats with the rdAc mutation tend to lose vision more slowly than LCA patients, typically not showing clinical signs until middle age. Research suggests this milder course is partly due to alternative splicing: the cat’s cells manage to produce some functional protein despite the mutation, buying extra years of usable vision.¹⁶ This kind of cross-species comparison is more than an academic curiosity; it helps researchers understand why some patients with a given mutation go blind in infancy while others retain vision for decades.

Gene Therapy and the Search for Treatments

There is currently no approved treatment that can halt or reverse PRA once it is underway in a pet dog or cat. But PRA has become one of the most productive testing grounds for retinal gene therapy, precisely because the genetic causes are so well characterized and the disease so closely mirrors retinitis pigmentosa in humans.

The most advanced gene therapy work in PRA has targeted the RPGR gene. In the XLPRA2 dog model, where a mutation in RPGR causes severe, early-onset retinal degeneration, researchers delivered a working copy of the gene to the retina using an adeno-associated virus vector injected beneath the retina. Dogs that received low and mid doses showed rescue of photoreceptor function on ERG and preservation of retinal structure on imaging, without signs of toxicity.¹⁷ These results helped support the move into human clinical trials for X-linked RP caused by RPGR mutations. The dogs, in other words, are not just patients; they are models driving human medicine forward.

Beyond gene replacement, other therapeutic avenues have been explored at various stages of development, including retinal transplantation, stem cell approaches, neuroprotective drugs, nutritional supplementation, and even retinal prosthetic devices.¹⁸ None of these are standard of care for PRA-affected pets yet. Antioxidant supplementation has attracted particular interest because oxidative stress appears to play a role in photoreceptor death. Laboratory work has shown that alpha-tocopherol (vitamin E) can protect retinal membranes from oxidative damage in vitro.¹⁹ However, a study of antioxidant supplements in healthy middle-aged dogs could not extrapolate its findings to dogs with retinal disease, and the authors cautioned that further work was needed.²⁰

Despite the thin evidence base, most board-certified veterinary ophthalmologists have prescribed at least one presumed neuroprotective therapy for dogs with degenerative retinal disease.²¹ These supplements and medications are used on a “probably won’t hurt, might help” basis. If your vet suggests them, that is the honest framing: the theoretical rationale is reasonable, but no one has demonstrated in a clinical trial that they slow PRA in dogs.

Living With a Blind Dog

Because PRA has no cure and gene therapy remains experimental, most owners of affected dogs eventually face the practical question of how to help a blind pet live well. The good news is that dogs adapt to blindness far better than most people expect. Their world is already dominated by smell and hearing, and in familiar surroundings many blind dogs navigate so confidently that visitors cannot tell they have lost their sight.

A few practical adjustments make a real difference. Keeping furniture in consistent locations removes the biggest source of confusion. Adding different textured rugs or mats near stairways and doorways gives the dog tactile landmarks. Scent markers, like a dab of vanilla extract near the back door, can help orient a dog in a larger home. Most importantly, talking to the dog frequently and using consistent verbal cues replaces the visual cues they can no longer read. Dogs that relied heavily on watching their owner’s face for guidance benefit from learning verbal commands they may not have needed before.

Outdoors, a leash or a fenced yard becomes non-negotiable. Some owners use a “halo” harness, a lightweight frame worn around the head that bumps into obstacles before the dog’s face does, particularly useful during the transition period when the dog is still mapping its environment by memory. Off-leash play in unfamiliar areas carries obvious risks, but familiar trails and enclosed spaces often work well once the dog has had a few supervised visits.

PRA as a Window Into Human Blindness

Nearly 100 dog breeds carry some form of PRA, and the genes involved frequently turn out to be the same ones responsible for retinitis pigmentosa in people.²² This overlap has made dogs with PRA some of the most valuable natural animal models in ophthalmology research. The similarity is not superficial: the clinical signs, disease course, diagnostic methods, and underlying molecular pathways are closely matched between canine PRA and human RP.

Gene discoveries in dogs have sometimes led researchers to look for the same genes in human patients who had no molecular diagnosis. When the prcd mutation was first characterized in dogs, the same gene was subsequently confirmed to cause RP in humans.²³ The Golden Retriever PRA gene SLC4A3 has similarly been proposed as a candidate for unsolved human retinal degenerations.²⁴ The traffic runs both ways: genes first identified in human RP patients are routinely checked in PRA-affected breeds, and vice versa. For families affected by inherited blindness in either species, research in one directly benefits the other.